Paris, January 3^rd, 2022 – The shareholders of Kurma Partners, an investment management company specializing in financing innovation in healthcare and biotechnology, have sold a controlling interest to Eurazeo. This transaction allows Kurma Partners to pursue its development strategy and to launch a third family of funds with a first growth vehicle. This initiative is supported by Eurazeo, which has become one of Kurma Partners’ reference investors and will invest significantly in its next vehicles, namely Growth Opportunity I and Kurma Biofund IV.

Download the Press Release